株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血糖自己測定器の世界市場

Global Self-monitoring Blood Glucose Market - Growth, Trends and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 808259
出版日 ページ情報 英文 105 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.68円で換算しております。
血糖自己測定器の世界市場 Global Self-monitoring Blood Glucose Market - Growth, Trends and Forecast (2020 - 2025)
出版日: ページ情報: 英文 105 Pages
担当者のコメント
下記の日本語概要は、最新版レポートの内容と異なる場合があります。詳細はお問合せください。
概要

当レポートでは、世界の血糖自己測定器市場を調査し、市場の概要、コンポーネント・エンドユーザー・地域別の市場規模の推移と予測、市場の成長要因および阻害要因、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査結果
  • 前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 成長要因
  • 阻害要因
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第5章 市場セグメンテーション

  • 自己血糖値測定器市場
    • コンポーネント別
      • 血糖値モニター
      • 試験紙
      • ランセット
    • エンドユーザー別
      • 病院
      • 個人
    • 地域別
      • 北米
      • 欧州
      • ラテンアメリカ
      • アジア太平洋地域
      • 中東・アフリカ

第6章 市場指標

  • 1型糖尿病の患者の推移と予測
  • 2型糖尿病の患者の推移と予測

第7章 競合情勢

  • 企業プロフィール
    • Abbott Diabetes Care
    • Roche
    • Johnson & Johnson
    • Arkray
    • Ascensia Diabetes Care
    • Agamatrix Inc.
    • Bionime Corporation
    • Acon
    • Medisana
    • Trivida
    • Rossmax
  • 企業シェア分析
    • Roche
    • Johnson & Johnson
    • Abboott Diabetes Care
    • その他

第8章 市場機会と将来展望

目次
Product Code: 65471

The Global Self-monitoring Blood Glucose market is expected to register a CAGR above 8% during the forecast period (2020-2025), and the market is estimated to reach around USD 15 billion by 2019.

The main diagnosis for diabetes patients is imbalances in blood glucose levels, which are not in compliance with the standard blood glucose levels. The general lab diagnostic tests can only help to diagnose the disease by the physicians. The patients with more fluctuations in glucose levels need to get it checked every day. Patients administering insulin need to check their blood glucose levels frequently, in order to adjust the doses of insulin or change the medication if necessary, which is only possible with the use of self-monitoring blood glucose devices. According to the National Mortality Database, diabetes contributed to over 17,000 deaths in 2017 (11% of all deaths). Diabetes was the underlying cause of death in around 4,800 deaths (28% of diabetes deaths). It was an associated cause of death in further 12,200 deaths (72% of diabetes deaths). According to the ADA (American Diabetes Association), the total assessed cost for diagnosed diabetes in 2018 was around USD 333 billion, which was inclusive of USD 242 billion in direct medical costs and USD 91 billion in augmented productivity.

Scope of the Report

The report includes a complete study on self-monitoring blood glucose, which includes glucometer devices, blood glucose test strips, and lancets. The study is further divided into hospital usage and home usage.

Key Market Trends

Most of the Glucometer Market Revenue is Generated from Blood Glucose Test Strips.

The Glucometer is considered to be a one-time purchase. However, test strips, on the other hand, are considered to be a continuous investment, as a test strip needs to be disposed of after one use. Thus, it presents a considerable cost impact to the consumers. Overall, the global demand for blood glucose test strips is projected to witness significant growth over the forecast period. The growth of the market studied is expected to be spurred by the rising global diabetic population. The growth in market volumes and share of the test strip is expected to be better than that of glucometers, because of the difference in the use-case frequency. While an average glucose meter lasts anywhere between six months and three years, presenting a one-time cost, during the same time frame, the corresponding use of multiple (in the range of thousands) test strips may occur, causing a recurrent cost impact.

North America has the Largest Market Share with a CAGR 9% in forecast period.

It was estimated that North America held 12% of the total diabetes population, and also it held approximately 6% of total type-1 diabetes patients in 2019. The high diabetes prevalence in North America region is due to the combination of high population rate associated with high obesity and lifestyle changes. It is estimated that North America has 22% of the worldwide obesity population. There is more carbohydrate consumption among the countries in the region, which is also one of the leading causes of obesity. The prevalence of diabetes has increased dramatically during the past two decades, which is a fact-driven by the increased prevalence of obesity and lifestyle changes. In North America diabetes ranks among the fast-growing chronic diseases in the United States.

Competitive Landscape

The global self-monitoring blood glucose market is highly consolidated, with few major manufacturers having a global market presence, while the remaining manufacturers confine to the other local or region-specific manufacturers. Mergers and acquisitions that occurred between the players in the recent past helped the companies to strengthen their market presence. Panasonic acquired Bayer's diabetes care unit and named it as Ascensia diabetes care, which continued its operations all over the world.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Self-monitoring blood glucose devices
    • 5.1.1 By Component (Value, and Volume, 2012 - 2025)
      • 5.1.1.1 Glucometer Devices
      • 5.1.1.2 Test Strips
      • 5.1.1.3 Lancets
    • 5.1.2 By End User
      • 5.1.2.1 Hospital Use (Value, and Volume, 2012 - 2025)
      • 5.1.2.1.1 Glucometer Devices
      • 5.1.2.1.2 Test Strips
      • 5.1.2.1.3 Lancets
      • 5.1.2.2 Personal Use (Value, and Volume, 2012 - 2025)
      • 5.1.2.2.1 Glucometer Devices
      • 5.1.2.2.2 Test Strips
      • 5.1.2.2.3 Lancets
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States (Value, and Volume, 2012 - 2025)
      • 5.2.1.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.1.1.2 By End User (Hospital Use and Personal Use)
      • 5.2.1.1.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
      • 5.2.1.2 Canada (Value, and Volume, 2012 - 2025)
      • 5.2.1.2.1 By Component (Glucometer Devices, Test Strips, Lancets)
      • 5.2.1.2.2 By End User (Hospital Use and Personal Use)
      • 5.2.1.2.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
      • 5.2.1.3 Rest of North America (Value, and Volume, 2012 - 2025)
      • 5.2.1.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.1.3.2 By End User (Hospital Use and Personal Use)
      • 5.2.1.3.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
    • 5.2.2 Europe
      • 5.2.2.1 France (Value, and Volume, 2012 - 2025)
      • 5.2.2.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.2.1.2 By End User (Hospital Use and Personal Use)
      • 5.2.2.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.2.2 Germany (Value, and Volume, 2012 - 2025)
      • 5.2.2.2.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.2.2.2 By End User (Hospital Use and Personal Use)
      • 5.2.2.2.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.2.3 Italy (Value, and Volume, 2012 - 2025)
      • 5.2.2.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.2.3.2 By End User (Hospital Use and Personal Use)
      • 5.2.2.3.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.2.4 Spain (Value, and Volume, 2012 - 2025)
      • 5.2.2.4.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.2.4.2 By End User (Hospital Use and Personal Use)
      • 5.2.2.4.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.2.5 United Kingdom (Value, and Volume, 2012 - 2025)
      • 5.2.2.5.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.2.5.2 By End User (Hospital Use and Personal Use)
      • 5.2.2.5.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.2.6 Russia (Value, and Volume, 2012 - 20245
      • 5.2.2.6.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.2.6.2 By End User (Hospital Use and Personal Use)
      • 5.2.2.6.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.2.7 Rest of Europe (Value, and Volume, 2012 - 2025)
      • 5.2.2.7.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.2.7.2 By End User (Hospital Use and Personal Use)
      • 5.2.2.7.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
    • 5.2.3 Latin America
      • 5.2.3.1 Mexico (Value, and Volume, 2012 - 2025)
      • 5.2.3.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.3.1.2 By End User (Hospital Use and Personal Use)
      • 5.2.3.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.3.2 Brazil (Value, and Volume, 2012 - 2025)
      • 5.2.3.2.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.3.2.2 By End User (Hospital Use and Personal Use)
      • 5.2.3.2.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.3.3 Rest of Latin America (Value, and Volume, 2012 - 2025)
      • 5.2.3.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.3.3.2 By End User (Hospital Use and Personal Use)
      • 5.2.3.3.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
    • 5.2.4 Asia-Pacific
      • 5.2.4.1 Japan (Value, and Volume, 2012 - 2025)
      • 5.2.4.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.1.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.2 South Korea (Value, and Volume, 2012 - 2025)
      • 5.2.4.2.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.2.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.2.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.3 China (Value, and Volume, 2012 - 2025)
      • 5.2.4.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.3.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.3.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.4 India (Value, and Volume, 2012 - 2025)
      • 5.2.4.4.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.4.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.4.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.5 Australia (Value, and Volume, 2012 - 2025)
      • 5.2.4.5.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.5.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.5.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.6 Vietnam (Value, and Volume, 2012 - 2025)
      • 5.2.4.6.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.6.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.6.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.7 Malaysia (Value, and Volume, 2012 - 2025)
      • 5.2.4.7.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.7.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.7.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.8 Indonesia (Value, and Volume, 2012 - 2025)
      • 5.2.4.8.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.8.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.8.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.9 Philippines (Value, and Volume, 2012 - 2025)
      • 5.2.4.9.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.9.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.9.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.10 Thailand (Value, and Volume, 2012 - 2025)
      • 5.2.4.10.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.10.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.10.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.11 Rest of Asia-Pacific (Value, and Volume, 2012 - 2025)
      • 5.2.4.11.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.11.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.11.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
    • 5.2.5 Middle-East and Africa
      • 5.2.5.1 Saudi Arabia (Value, and Volume, 2012 - 2025)
      • 5.2.5.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.5.1.2 By End User (Hospital Use and Personal Use)
      • 5.2.5.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.5.2 Iran (Value, and Volume, 2012 - 2025)
      • 5.2.5.2.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.5.2.2 By End User (Hospital Use and Personal Use)
      • 5.2.5.2.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.5.3 Egypt (Value, and Volume, 2012 - 2025)
      • 5.2.5.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.5.3.2 By End User (Hospital Use and Personal Use)
      • 5.2.5.3.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.5.4 Oman (Value, and Volume, 2012 - 2025)
      • 5.2.5.4.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.5.4.2 By End User (Hospital Use and Personal Use)
      • 5.2.5.4.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.5.5 South Africa (Value, and Volume, 2012 - 2025)
      • 5.2.5.5.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.5.5.2 By End User (Hospital Use and Personal Use)
      • 5.2.5.5.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.5.6 Rest of Middle-East and Africa (Value, and Volume, 2012 - 2025)
      • 5.2.5.6.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.5.6.2 By End User (Hospital Use and Personal Use)
      • 5.2.5.6.3 By Company (Roche, Abbott, Johnson & Johnson and Others)

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population (2012-2025)
  • 6.2 Type-2 Diabetes Population (2012-2025)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Abbott Diabetes Care
    • 7.1.2 Roche
    • 7.1.3 Johnson & Johnson
    • 7.1.4 Arkray
    • 7.1.5 Ascensia Diabetes Care
    • 7.1.6 Agamatrix Inc.
    • 7.1.7 Bionime Corporation
    • 7.1.8 Acon
    • 7.1.9 Medisana
    • 7.1.10 Trivida
    • 7.1.11 Rossmax

8 MARKET OPPORTUNITIES AND FUTURE TRENDS